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Key Points 
• 1 in 5 older patients in England were discharged with potentially inappropriate medication 
(PIMs), defined by the 2015 Beers Criteria. 
• Patients prescribed PIMs at hospital discharge were not at increased risk of hospitalisation 
or mortality, however multiple PIMs at discharge increased the risk of adverse drug 
reactions.  
• The 2015 Beers Criteria may have a limited clinical utility in UK settings.  
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Objectives To investigate if inappropriate prescribing, defined by the Beers Criteria (2015 
version), is associated with medication-related harm (MRH), hospital admission, and 
mortality in older adults.  
Design Multicentre, prospective cohort study 
Setting South-England 
Participants 1280 older adults (median age 82 years) recruited at hospital discharge 
between 2013 and 2015 and followed-up by senior pharmacists in the community 
Main outcomes MRH (harm from adverse drug reactions, non-adherence, and medication 
errors) was identified at 8-weeks post-discharge using three data sources; hospital 
readmissions, GP records, and, patient interview.   One-year mortality was determined using 
hospital records.  Potentially inappropriate medications (PIMs) were determined using 
Beers 2015 criteria for medicines to avoid in older adults.  Logistic regression was used to 
investigate the relationship between patients prescribed PIMs and adverse outcomes.     
Results Two hundred and seventy-six patients (22%) were prescribed one or more PIMs at 
hospital discharge.  The main PIM classes prescribed at hospital discharge were 
benzodiazepines and related drugs (30%) and antidepressants (27%).  1116 out of 1280 
patients completed follow-up and 413 (37%) experienced MRH.  In 51 cases (12%), MRH was 
attributable to a PIM.  There was no significant relationship between patients prescribed 
PIMs and overall MRH, hospital readmission or all-cause one-year mortality.  Multiple PIMs 
at discharge was independently associated with an increased risk of ADR (OR 2.32, 95% CI 
1.03-5.23).     
Conclusions The prescribing of PIMs is common at hospital discharge of older adults in 
England.  The 2015 Beers criteria have a limited clinical value to predict adverse outcomes 












Reducing medication-related harm (MRH) has been designated the World Health 
Organisation’s third global patient safety challenge, with risk during transitions of care a 
specific priority [1].  This term, MRH, includes harm to individuals from adverse drug 
reactions, non-adherence and medication errors.  Older adults are at high risk of MRH due 
to their multimorbidity, polypharmacy and age-related changes in pharmacokinetics and 
pharmacodynamics[2].  A recent systematic review of MRH in older adults found that 
between 17-51% of older adults experience MRH within 30 days of hospital discharge[3].   In 
England, MRH is leading to an increasing number of hospital admissions[4].  The direct 
healthcare costs of MRH in older adults following hospital discharge in England is 
conservatively estimated at £400 million annually, of which 90% of cost is attributable to 
hospital readmission[5].  
        
Inappropriate prescribing is an avoidable risk factor for MRH in older adults and can be 
defined as medicines with a higher probability of causing harm than benefit to the 
individual[6].  Numerous explicit lists of medicines to avoid in older adults are available (e.g. 
Beers, STOPP, EU-PIM, PRISCUS criteria etc.) [7].  They have generally been developed 
through Delphi consensus amongst expert geriatricians and clinical pharmacologists. The 
Beers Criteria were the first published guidance of potentially inappropriate medicines 
(PIMs) to avoid in older adults, developed in the USA in 1991 for use with nursing home 
residents[8].  They have been updated several times since 1991, and are arguably the most 
established of the available lists.  Indeed, many other lists are derived from the Beers 
Criteria[7].  Crucially they are the only criteria where the strength of evidence for 
recommendations is reported [9].  The applicability of the Beers Criteria across care settings 
and in Europe has increased with updates[10]. In the UK, a cross-sectional analysis of almost 
14000 primary care patients in 2012 found that 38% were prescribed at least one Beers 
Criteria inappropriate medicine[11].  However, there has not been an investigation in the UK 
to determine whether PIM use (as defined by the Beers Criteria) is associated with adverse 
clinical outcomes such as MRH, hospitalisation and mortality.  
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In this study, we sought to determine if the 2015 Beers Criteria can predict adverse clinical 




This study was approved by the National Research Ethics Service, East of England (REC 
Reference 13/EE/0075). 
 
To investigate the relationship between Beers Criteria PIMs and adverse outcomes, we used 
data from the multicentre, prospective cohort PRIME study[5,12].  Detailed methods are 
available in the published protocol.[12] Between 2013 and 2015, adults aged 65 years and 
over were recruited from medical wards in five hospitals in England just prior to hospital 
discharge.  Patients were excluded if they were terminally ill, lacked capacity with no 
consultee, or if they were transferred to other healthcare units.  
Trained research nurses collected baseline data from participants, and research pharmacists 
followed participants for 8 weeks in the community to identify MRH. Medication-related 
harm (MRH) included adverse drug reactions (ADR) and harm arising from a failure to 
receive medication owing to non-adherence.  Harm arising from medication error was 
included where reported.  Intentional overdose was excluded. This is a modified version of 
the definition by Strand et al.[13]  
We identified MRH using three data sources; (1) participant (or carer if needed) telephone 
interview using a structured questionnaire, (2) General Practitioner (GP) records, and, (3) 
prospective review of hospital readmissions, in consultation with the admitting medical 
consultant.  Where an ADR was suspected, we used the validated Naranjo Algorithm [14] to 
assess causality along with the British National Formulary and Summary of Product 
Characteristics.  We assessed participants’ non-adherence to medicine using a modified 
version of a validated questionnaire. [15]  
An endpoint committee, independent from data collection, consisting of three senior 
geriatricians and a senior researcher in clinical pharmacy and therapeutics were provided 
structured case summaries of all cases of MRH by the research pharmacists.  The committee 
reviewed, scrutinised and confirmed or rejected MRH cases by consensus.  All-cause 
mortality was identified at one-year post-discharge using patient hospital records.  
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We determined inappropriate prescribing at hospital discharge using Table 2 of the Beers 
Criteria ‘American Geriatrics Society 2015 criteria for potentially inappropriate medication 
use in older adults’ [8].  We used these criteria, and cross-referenced to a published UK 
modification[11]. We applied the 2015 Beers Criteria that had a moderate (or above) grade 
of evidence. 
Statistical analysis  
The distributions of variables were examined using histograms and were described by their 
medians and interquartile ranges (IQR) due to evident skewness.  For categorical variables, 
numbers and percentages were used to describe the data. Associations between variables 
and PIMs use was evaluated using the Mann-Whitney U-test for continuous variables and 
Fisher’s Exact test for categorical variables.   Logistic regression models were used to 
investigate the relationship between PIMs and adverse outcomes (MRH, ADR only, hospital 
readmissions and all-cause mortality).  Models were adjusted for age, gender, 
socioeconomic status (using the Index of Multiple Deprivation for England), comorbidity 
(using the Charlson comorbidity index), number of drugs, and functional status (using the 
Barthel index).  We analysed data using IBM SPSS Statistics, version 22, IBM Corporation, 





Baseline characteristics and PIMs prescribed at hospital discharge 
We recruited 1280 older adults (median age 82, IQR 75-87 years; 58% female) close to the 
time of hospital discharge.  The characteristics of the study population discharged with and 
without PIMs are shown in Table 1. Out of this cohort, a total of 276 (21.6%) patients were 
prescribed at least one PIM and 35 (2.7%) were prescribed two or more PIMs.  Compared to 
patients without PIMs at hospital discharge, those patients with PIMs were more likely to be 










There was a total of 315 prescriptions for 36 different PIMs (see Table 2).  The main PIMs 
prescribed at hospital discharge were benzodiazepines and related hypnotics (n=94, 30%) 




MRH identified at 8-week follow-up 
Of those recruited, 164 (12.8%) did not complete follow-up to determine whether they 
experienced MRH and were therefore excluded from further analyses.  There were no 
significant differences in the baseline characteristics between included and excluded 
participants, with the exception that included participants were more functionally 
dependent than excluded participants (Barthel Index 17 versus 18 out of 20, P=0.04).  Out of 
the 1116 participants that completed follow-up, 240 (21.5%) had been discharged with at 
least one PIM (21.6% in the full cohort of 1280 participants) and 31 (2.8%) discharged with 
two or more PIMs (2.7% in the full cohort).   
 
Four hundred and thirteen participants out of 1116 (37%) experienced MRH within 8-weeks 
post-discharge[5].  Antihypertensives (22.4%), opiates (17.2%), diuretics (12.2%) and 
antibiotics (10.5%) were implicated in the highest proportion of MRH events.  Adverse drug 
reactions were responsible for MRH in 301 out of 413 cases (72.9%), non-adherence in 45 
cases (10.9%), and a medication error in 14 cases (3.4%).  In five cases (1.2%) the patient 
experienced harm from both an ADR and a medication error, and in 48 cases (11.6%) harm 
was due to both an ADR and non-adherence.  Overall, 284 patients (25.4%) were readmitted 
to hospital within 8 weeks, and MRH was the primary reason for readmission in 87 (30.6%) 
out of the total number of readmissions.  One year following hospital discharge, 240 
participants had died (21.5%).  
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MRH due to PIMs at 8-weeks follow-up 
We identified 51 participants that experienced MRH due to PIMs.  This represents 12.3% of 
all participants who experienced MRH (n=413). There were 57 MRH events specifically 
attributable to PIMs.  The PIMs that most commonly caused MRH were benzodiazepines 
and hypnotics (n=15, 26%), and antidepressants (n=14, 25%).  
 
Table 3 shows the unadjusted and adjusted relationships between PIM use and adverse 
outcomes, including MRH, hospital readmission and all-cause mortality at one-year.  On 
multivariable analysis, PIM use as defined by the 2015 Beers Criteria was not associated 
with MRH (OR 1.02, 95% CI 0.74-1.42, P=0.90), ADR specifically (OR 1.16, 95% CI 0.82-1.65, 
P=0.40), hospital readmission (OR 1.20, 95% CI 0.84-1.72, P=0.31), MRH-specific hospital 
readmission (OR 1.14, 95% CI 0.65-1.99, P=0.65) or all-cause mortality (OR 0.75, 95% CI 
0.48-1.18, P=0.22).  However, a statistically significant relationship was found between 







Our main findings are that 1 in 5 older people are prescribed PIMs at hospital discharge, 
defined by the 2015 Beers Criteria, however PIM use has a limited relationship with adverse 
clinical outcomes. Indeed, this might be expected given that MRH could only be attributed 
to PIMs in 12% of the 413 patients that experienced MRH in the study.  The prescription of 
PIMs in our UK cohort did not confer a higher risk of MRH (ADR, harm from non-adherence 
and harm from medication error) or hospital readmission at 8-weeks post-discharge or 
increased mortality risk over one year.  However multiple PIM prescription was associated 
with the incidence of ADR at an 8-week follow-up.  This is the first UK study to investigate 
the relationship between the 2015 Beers Criteria PIMs and MRH. Hospital discharge is a 
crucial opportunity to optimise medicines and reduce patient risk of MRH, but it remains 
unclear what tool practitioners should use to identify high-risk individuals [16,17].   
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Using the UK Clinical Practice Research Datalink (CPRD), a retrospective analysis of almost 
14000 older adults showed that 38% of the cohort had at least one PIM as defined by the 
2012 Beers Criteria[11].  In our study, the prevalence was lower (22%) which might reflect a 
national drive in England to optimise medicines whilst patients are in the hospital 
setting[18,19].  Our prevalence rate of 22% was consistent with a large Italian study, which 
found that 24% of participants were discharged with a PIM based on Beers Criteria[20].   
Previous studies that applied the Beers Criteria to predict MRH in a European setting have 
shown mixed results.  In a prospective cohort study of older hospitalised patients in Ireland, 
29% of patients were found to be prescribed a PIMs on admission (based on Beers 2003 
version). However no significant relationship was found between PIMs use and medicines-
related hospital admission (OR 1.28, 0.95-1.72; P=0.11)[21].  Similarly, no relationship was 
found between PIMs use (based on Beers 2012 version) and adverse clinical outcomes in a 
study of older Italians that were followed up for 3 months after hospital discharge (OR 0.88, 
95% CI 0.49-1.51)[20].  In contrast, a multicentre study in Italy of 871 older inpatients, found 
that the 2012 Beers criteria did predict a combined adverse outcome of ADR and functional 
decline (OR 1.74, 95% CI 1.06-2.85) [22].   Additionally, a Dutch study of preventable 
medication-related hospital admission found that two or more PIMs (based on Beers 2012 
criteria) independently predicted hospital admissions in older adults [23].  
 
There are two important reasons that may explain the lack of association found in our study 
between PIMs use and adverse outcomes.  Firstly explicit lists used in isolation fail to 
account for the interplay of biological, psychological and social complexities that places 
patients at high risk of MRH.   A personalised approach that combines knowledge of both 
PIMs and patient-specific complexities is needed to prescribe appropriately. In the BELFRAIL 
cohort of older Belgian community-dwelling patients PIMs use was common, however in 
30% of these patients the medicines were in fact not considered inappropriate by an expert 
panel (including a Geriatrician, General Practitioner and Clinical pharmacist) having 
considered the patient’s full clinical picture [24].  A study of older outpatients of one large 
medical centre in the US similarly demonstrated the discordance between individualised 
medicine reviews by experts (physician/pharmacist pair) and medicines identified as 
inappropriate using two different explicit lists (Beers Criteria and Zhan Criteria).[25]  In this 
study, 61% of medicines identified as inappropriate by the Beers Criteria were not judged to 
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be problematic based on individualised expert assessment (and 49% of medicines identified 
by the Zhan Criteria).   Another important reason that the Beers Criteria may not be 
predictive of adverse events is that many of the medicines listed are not licensed or 
commonly used in England.[11]   
The STOPP criteria developed in Ireland through Delphi consensus methodology are an 
alternative tool to the Beers Criteria.  Whilst there is some evidence that applying the STOPP 
criteria can prevent adverse outcomes for inpatient and care home populations, evidence 
for their ability to prevent adverse outcomes in community-dwelling older adults is 
limited[26].  A recent cross-European study trialled the use of the STOPP criteria within a 
risk prediction tool to identify hospital patients at high risk of ADR but the results showed 
limited clinical value (area under the receiver-operating-curve = 0.59) [27]. A similarly poor 
predictive ability was found in a Swedish study investigating the ability of STOPP to predict 
rehospitalisation and mortality in older patients following hospital discharge (area under the 
receiver-operating-curve = 0.57).[28]   
 
There are some important limitations to our findings.  Firstly, a sample size calculation was 
not specifically performed for the hypothesis tested in this study and the precision of our 
results should be interpreted in view of this.  Secondly, in line with some other 
studies[20,29,30], we only applied the 2015 Beers Criteria for drugs to avoid in all older 
adults (excluding criteria for drug-disease combinations).  One criterion (avoid use of 
proton-pump inhibitors (PPI) for more than 8 weeks unless for high-risk patients) was not 
applied due to incomplete information on duration of PPI use.  Thirdly, our follow-up period 
for MRH was limited to 8 weeks as we were interested in the immediate post-discharge 
period, however MRH could have occurred after this observation period.  Fourthly, 12.8% of 
patients were lost to follow-up which may introduce some selection bias, however there 
were no clinically significant differences between those included and excluded.  Finally, our 
results are based on prescribing practices in hospitals in the South of England and may not 
be generalisable to other settings.     
 
In conclusion, inappropriate prescribing, as defined by the 2015 Beers Criteria, was found to 
be common at hospital discharge in a large cohort of older adults from five UK hospitals.  
Patients prescribed PIMs were not at increased risk of MRH (inclusive of harm from ADR, 
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non-adherence and medication error), or hospital readmission, or one-year mortality.  
Patients prescribed multiple PIMs were, however, at increased risk of ADR post discharge.  
Identifying older patients at risk of MRH is clinically complex, and the 2015 Beers criteria 
had limited value to predict adverse clinical outcomes in a UK cohort of older adults.  
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Table 1. Baseline characteristics of patients discharged with and without PIMs  
Characteristic Patients without PIM 
(n=1004) 
Patients with PIM 
(n=276) 
P-value 
Age, median (IQR), years  81.9 (75.5-87.1) 80.7 (74.7-85.7) 0.056 
Female, n (%) 567 (56.5) 178 (64.5) 0.019 







Abbreviated Mental Test 
Score (AMTS), median 
(IQR)a 
10 (8-10) 9 (9-10) 0.621 
Barthel Index, median (IQR) 18 (13-20) 17 (13-19) 0.374 
Number of discharge 
medicines, median (IQR)b 
 
8 (6-11) 11 (9-13.8) <0.001 









Living alone after discharge, 
n (%)c 
489 (48.9) 142 (51.6) 0.454 
Socioeconomic status, 
median (IQR), IMD deciled 
5 (3-8) 5 (2-8) 0.240 
IQR, interquartile range; IMD, Index of Multiple Deprivation.  
Mann-Whitney U test for continuous variables and Fisher’s Exact test for categorical variables.  







Table 2. Main classes of PIM prescribed at hospital discharge  
Medicine Class Medicines Total Number (%) 
Benzodiazepenes and 
related drugs 
Zopiclone (24), Temazepam (19), 
Diazepam (17), Lorazepam (14), 
Nitrazepam (7), Zolpidem(6), 
Clonazepam (5), Lormetazepam (1), 
Oxazepam (1)  
 
94 (29.8) 
Antidepressants  Amitriptyline (68), Paroxetine (7), 
Nortriptyline (3), Trimipramine (3), 
Clomipramine (2), Imipramine (2) 
 
85 (27.0) 




Propulsives Metoclopramide (22) 22 (7.0) 
Antihistamines Chlorphenamine (12), Promethazine 




Antipsychotics Prochlorperazine (12), Haloperidol 
(2), Risperidone (2) 
 
16 (5.1) 
Other Digoxin (9), Amiodarone (5), 
Nifedipine Immediate Release (5), 
Insulin sliding scale (3), Dipyridamole 
(2), Phenobarbital (2), Primidone (2), 
Ibuprofen (2), Naproxen (1), 
Dicyclomine (1), Oral Estrogen (1), 



















Table 3. Univariable and multivariable analysis of the relationship between PIM use and adverse 
outcomes (n=1116) 











Beers Criteria PIMs Univariable Odds Ratios (95% CI) 
No PIM Reference Reference Reference Reference Reference 
 























Beers Criteria PIMs Adjusted Odds Ratios (95% CI) a 
No PIM  Reference Reference Reference Reference Reference 
 























 a92 missing cases.  Analyses adjusted for age, gender, socioeconomic status, Charlson Comorbidity Index, number of drugs, Barthel Index 
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